Constructive Bio

In this blog, Albert Maguire-King, Media and Communications Executive at the BIA, shares the vision of hope witnessed at BIA's recent TechBio X event in Cambridge.

The shape of the political landscape that our sector will navigate this year became clear at the Labour Party conference in Liverpool last week. The new Labour government will unveil its industrial strategy, hold a Global Investment Summit, and meet with the Life Science Council before the key moment of the Budget on 30 October.

Financing led by Ahren, OMX Ventures and Paladin Capital Group represents one of the largest UK biotech Series A rounds in recent years.

Constructive Bio is recoding biology to design novel organisms, molecules and products. Their platform reprograms the fundamental protein translation process, turning cells into bio-renewable factories for producing novel molecules that nature could not make before. They are also rewriting new genomes from scratch to engineer unnatural polymers. Read this TechBio innovator spotlight to learn more about how the technology works and how it will be used.

The BIA is driving progress across life sciences, from shaping policy in engineering biology and advocating for balanced perspectives in the Covid Inquiry to exhibiting UK innovation at JP Morgan Healthcare Week.